Abstract
Abstract
Introduction
For the analysis of clinical effects, multiple imputation (MI) of missing data were shown to be unnecessary when using longitudinal linear mixed-models (LLM). It remains unclear whether this also applies to trial-based economic evaluations. Therefore, this study aimed to assess whether MI is required prior to LLM when analyzing longitudinal cost and effect data.
Methods
Two-thousand complete datasets were simulated containing five time points. Incomplete datasets were generated with 10, 25, and 50% missing data in follow-up costs and effects, assuming a Missing At Random (MAR) mechanism. Six different strategies were compared using empirical bias (EB), root-mean-squared error (RMSE), and coverage rate (CR). These strategies were: LLM alone (LLM) and MI with LLM (MI-LLM), and, as reference strategies, mean imputation with LLM (M-LLM), seemingly unrelated regression alone (SUR-CCA), MI with SUR (MI-SUR), and mean imputation with SUR (M-SUR).
Results
For costs and effects, LLM, MI-LLM, and MI-SUR performed better than M-LLM, SUR-CCA, and M-SUR, with smaller EBs and RMSEs as well as CRs closers to nominal levels. However, even though LLM, MI-LLM and MI-SUR performed equally well for effects, MI-LLM and MI-SUR were found to perform better than LLM for costs at 10 and 25% missing data. At 50% missing data, all strategies resulted in relatively high EBs and RMSEs for costs.
Conclusion
LLM should be combined with MI when analyzing trial-based economic evaluation data. MI-SUR is more efficient and can also be used, but then an average intervention effect over time cannot be estimated.
Funder
Amsterdam Public Health Research Institute
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference55 articles.
1. WHO: 2015 Global Survey on Health Technology Assessment by National Authorities, https://www.who.int/health-technology-assessment/examples/en/, (2015)
2. Drummond, M.F., Sculpher, M.J., Torranc, G.W.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2005)
3. Petrou, S., Gray, A.: Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. The BMJ (2011). https://doi.org/10.1136/bmj.d1548
4. Rubin, D.B.: Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons (2004)
5. Faria, R., Gomes, M., Epstein, D., White, I.R.: A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 32, 1157 (2014). https://doi.org/10.1007/s40273-014-0193-3